A organização de uma diretriz clínica é tarefa complexa, que necessariamente deve
envolver planejamento prévio, coordenação apropriada, revisão aprofundada da literatura …

Abstract Sacubitril/valsartan (LCZ696) is indicated for the treatment of heart failure with
reduced ejection fraction. Absorption of sacubitril/valsartan and conversion of sacubitril …

A organização de uma diretriz clínica é tarefa complexa, que necessariamente deve
envolver planejamento prévio, coordenação apropriada, revisão aprofundada da literatura …

It has been known since the 1990s that long-term morbidity and mortality is improved in
patients with heart failure with reduced ejection fraction (HFrEF) by treatments that target the …

Aims Sacubitril/valsartan (SV) reduced heart failure hospitalization and cardiovascular
mortality compared with enalapril in the Prospective Comparison of ARNI with ACE‐I to …

Real-life data confirming the favourable renal outcome in patients with heart failure (HF)
treated with Sacubitril/Valsartan, previously found in several trials (RCTs), are still scant. We …

Chronic kidney disease (CKD) is a global public health problem, and cardiovascular
disease is the most common cause of death in patients with CKD. The incidence and …

Heart failure (HF) is a significant public health concern characterized by notable rates of
morbidity and mortality. Multimorbidity, ranging from 43% to 98% among HF patients …

Background: Heart failure (HF) is one of the main comorbidities in patients receiving
maintenance hemodialysis (HD). Sacubitril/valsartan (SAC/VAL) is widely used in HF …

What is known and objective Angiotensin receptor‐neprilysin inhibitor (ARNi) therapy has
been shown to improve cardiovascular outcomes in the Prospective Comparison of ARNi …